Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Sep 30, 2012
Filed with the SEC on Nov 6, 2012 and accepted by EDGAR at Nov 6, 2012, 21:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-07-01 to 2012-09-30 | $336.0m | us-gaap:Revenues |
| Revenue | 9 months2012-01-01 to 2012-09-30 | $1.19bn | us-gaap:Revenues |
| Cost of revenue | 3 months2012-07-01 to 2012-09-30 | $30.7m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2012-01-01 to 2012-09-30 | $161.1m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2012-07-01 to 2012-09-30 | $200.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2012-01-01 to 2012-09-30 | $593.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-07-01 to 2012-09-30 | $97.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2012-01-01 to 2012-09-30 | $326.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-07-01 to 2012-09-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2012-01-01 to 2012-09-30 | $79.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-07-01 to 2012-09-30 | $4.6m | us-gaap:InterestExpense |
| Interest expense | 9 months2012-01-01 to 2012-09-30 | $12.9m | us-gaap:InterestExpense |
| Income tax | 3 months2012-07-01 to 2012-09-30 | $21.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2012-01-01 to 2012-09-30 | $41.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-07-01 to 2012-09-30 | −$57.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2012-01-01 to 2012-09-30 | −$30.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-07-01 to 2012-09-30 | −$0.27 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2012-01-01 to 2012-09-30 | −$0.15 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-07-01 to 2012-09-30 | −$0.27 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2012-01-01 to 2012-09-30 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2012-07-01 to 2012-09-30 | 213,767,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2012-01-01 to 2012-09-30 | 211,053,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months2012-01-01 to 2012-09-30 | $43.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-09-30 | $436.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-09-30 | $1.63bn | us-gaap:AssetsCurrent |
| Total assets | At period end2012-09-30 | $2.72bn | us-gaap:Assets |
| Current liabilities | At period end2012-09-30 | $406.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-09-30 | $1.45bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-09-30 | $1.03bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001047469-12-010125. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.